Thu Sep 19 03:47:00 UTC 2024: ## Blood Tests May Offer Early Detection of Alzheimer’s Disease
**Boston, MA –** Scientists have made a breakthrough in the fight against Alzheimer’s disease, identifying blood-based biomarkers that can predict the progression from mild cognitive impairment (MCI) to dementia. This discovery offers hope for earlier diagnosis and potential intervention before irreversible damage occurs.
The research, published in the journal Alzheimer’s & Dementia, was conducted by teams at Boston University, Indiana University School of Medicine, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for Neurodegenerative Diseases (DZNE). The researchers analyzed the plasma microRNAome of participants with varying cognitive abilities, including those with normal cognition, MCI, and Alzheimer’s disease.
MicroRNAs, tiny molecules that regulate gene expression, proved to be crucial indicators of Alzheimer’s progression. The researchers found that certain microRNA patterns in the blood can predict which individuals with MCI are likely to develop full-blown dementia.
“Our discovery is important because, unlike the current biomarkers, microRNAs may serve as blood molecular biomarkers years before Alzheimer’s disease manifests clinically, thus identifying the time window for effective prevention or early intervention to stop the progression of Alzheimer’s,” explained Dr. Ivana Delalle, a senior author on the study.
These findings provide a roadmap for developing new diagnostic tools and potential therapeutic targets for Alzheimer’s disease, paving the way for more effective prevention and treatment strategies.
“While these are exciting times with novel therapies for Alzheimer’s disease entering clinical care, the researchers note that those therapies only will work in a real-world setting if patients at risk are identified as early as possible,” stated Andrew J. Saykin, another senior author.
The researchers believe that blood miRNA analysis could be used in a point-of-care setting, making early detection of Alzheimer’s more accessible. This new tool holds the potential to revolutionize the way Alzheimer’s is diagnosed and treated, giving patients and their families a much-needed advantage in the battle against this debilitating disease.
First Piper 